Document Type
Article
Publication Date
1-1-2018
Publication Title
Rev Urol
Keywords
Androgen deprivation therapy; LHRH agonist; Leuprolide acetate; Nadir testosterone; Prostate cancer
Abstract
Evidence suggests lower nadir testosterone levels during the first year of androgen deprivation therapy improve advanced prostate cancer clinical outcomes. We evaluated pivotal trials for subcutaneously administered leuprolide acetate (1-, 3-, 4-, and 6-month doses) to determine nadir testosterone levels. Pooled analysis showed 99%, 97%, and 91% of patients reached nadir testosterone ≤20, ≤10, and ≤5 ng/dL respectively (median ≤3 ng/dL). Across all available categories, $88% of patients reached nadir testosterone ≤5 ng/dL, and
Clinical Institute
Cancer
Department
Oncology
Recommended Citation
Pieczonka, Christopher M; Twardowski, Przemyslaw; Renzulli, Joseph; Hafron, Jason; Boldt-Houle, Deborah M; Atkinson, Stuart; and Eggener, Scott, "Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients." (2018). Articles, Abstracts, and Reports. 1010.
https://digitalcommons.providence.org/publications/1010